The GPhC must demonstrate equivalence before shortening the international registration route

In April 2026, the General Pharmaceutical Council (GPhC) launched a consultation on draft standards for internationally qualified pharmacists who want to register in Great Britain^​1​. At present, pharmacists who qualified outside the European Economic Area (EEA), European Free Trade Association (EFTA) countries and Switzerland must complete the Overseas Pharmacists’ Assessment Programme (OSPAP), a foundation training year and the Common Registration Assessment before applying to register. The proposal would replace this with a single year of integrated academic learning and learning in practice, with independent prescribing built into the route and prior learning and experience capable of recognition^​1​.

Internationally qualified pharmacists should have a fair and proportionate route into Great Britain’s workforce, but a shortened route to the same professional register requires a clear evidential foundation. The central question the consultation does not yet answer is whether the GPhC can demonstrate that the proposed single integrated year — incorporating independent prescribing and recognition of prior learning — provides equivalent assurance to the existing route in terms of upstream education quality, supervised practice and patient-safety safeguards^​1​.

Arguments for reform

There are reasonable arguments for reform. Internationally qualified pharmacists may already have significant knowledge and professional experience. Unnecessary duplication should be avoided, and the Professional Qualifications Act 2022 requires regulators to consider whether requirements create unnecessary barriers for internationally qualified professionals^​2,3​. The GPhC is therefore right to consider proportionality, flexibility and workforce access. However, removing unnecessary duplication is not the same as demonstrating equivalence.

The central concern is whether the proposed route gives the GPhC sufficient visibility into how that prior education was delivered and assessed. UK MPharm students enter a pathway in which the GPhC accredits providers, sets programme standards and scrutinises learning outcomes. UK universities also operate within domestic higher-education quality systems, including sector reference points such as the UK Quality Code^​4,5​.

Question 2.3 of the consultation document proposes evidence criteria for recognising prior learning, including qualifications based on national pharmacist education standards and learning outcomes verified by the GPhC as equivalent^​1​. This helps at model level but the consultation is less clear on practical assurance: how the GPhC would know those standards are implemented, assessed and enforced consistently by the original provider. If overseas universities are not accredited or audited by the GPhC in the way UK pharmacy schools are, the final standards should set out the alternative assurance process for admissions standards, assessment integrity, clinical exposure, placement quality, faculty standards and regulatory oversight^​1,4​.

The GPhC acknowledges that international pharmacy education varies: in some countries, education and training may be very similar to Great Britain’s system, while in others there may be significant differences, particularly where initial education is more science-focused than patient practice-focused^​1​. As a result, a shortened conversion route has to do more than map written outcomes. It must identify the nature and scale of each applicant’s gap, determine what cannot safely be waived and show how the remaining gaps will be remediated within a one-year model.

The proposed reduction also creates a specific evidential question: how much of the current two-year route is duplication and how much is supervised practice exposure that cannot safely be compressed? The consultation says the integrated model is a crucial reason for shortening training, because it allows trainees to apply knowledge immediately and reduces the risk of duplicated learning^​1​. That may justify some streamlining, but adding independent prescribing into the same year raises the evidential threshold further. Prescribing is not simply an extension of pharmaceutical knowledge. It requires clinical assessment, diagnostic reasoning, risk management, legal accountability, referral thresholds, monitoring decisions, safeguarding awareness and familiarity with NHS systems and GB prescribing governance.

Independent prescribing status

There is also a fairness and public-confidence issue. UK-trained pharmacists who joined the register before 2026 do not automatically hold independent prescribing status; they must complete a separate GPhC-accredited prescribing course. The proposed route would instead build independent prescribing into the integrated year for internationally qualified pharmacists^​1​. That is only defensible if the GPhC clearly evidences equivalence in prior education, supervised GB practice, prescribing assessment and patient-safety safeguards.

Recognition of prior learning also requires tighter control. The consultation proposes that programme providers can evaluate and recognise prior learning and experience, can shorten the period of education and training where all outcomes can be met, and will be supported by GPhC guidance intended to promote consistency^​1​. That still leaves an operational risk: two candidates with similar backgrounds could receive materially different routes if providers interpret the guidance differently. Any decision to shorten training should therefore be evidence-based, auditable, independently moderated and consistently applied.

The wider workforce consequences require regulatory attention before implementation. The GPhC notes that approximately 400 OSPAP students complete the programme each year across four providers. A compressed route may increase international throughput, but the consultation does not model whether existing placement infrastructure can absorb that increase. Community pharmacies and NHS settings providing supervised practice are already under pressure from domestic foundation trainee demand following the expansion of UK MPharm programmes; adding a further cohort without assessing supervision capacity creates an operational risk that the standards should address. The GPhC should publish projected intake figures, placement capacity analysis, supervision demand modelling and an assessment of interaction with domestic training expansion — alongside its plans for monitoring workforce distribution outcomes after implementation. These are regulatory planning obligations, not objections to international registration.

Safeguarding steps to a shorter programme

A more defensible route to shortening the OSPAP programme would include four safeguards. 

First, the GPhC should publish the full evidence base for its equivalence assessment: both the comparative analysis of international pharmacy education systems against GPhC-accredited UK MPharm provision, and the rationale for compressing the existing two-year route to one year while simultaneously incorporating independent prescribing. Where overseas universities are not directly accredited or audited by the GPhC, the final standards must identify the alternative assurance process used to establish comparability across admissions standards, assessment integrity, clinical exposure, placement quality, faculty standards and regulatory oversight. Where compression of the existing route is justified by the elimination of duplication, the evidence for that determination should be published. Where faster attainment of competence is expected, the basis for that expectation must be made explicit.

Second, recognition of prior learning should be governed by mandatory national criteria, not broad provider discretion. The consultation proposes that programme providers can evaluate and recognise prior learning, shorten training where all outcomes can be met and will be supported by GPhC guidance intended to promote consistency^​1​. That model creates a material consistency risk: two candidates with comparable backgrounds presenting to different providers could receive substantially different training pathways, with no structural mechanism to identify or correct divergence. RPL decisions should instead be subject to mandatory national criteria with defined minimum evidential thresholds, independent moderation across providers and a published audit trail — with the GPhC, not individual providers, retaining final accountability for any reduction below the baseline training period.

Third, there should be a non-waivable minimum period of supervised GB practice, including exposure to NHS systems, GB pharmacy law, clinical governance, safeguarding, responsible pharmacist duties, patient-facing care and professional accountability.

Fourth, prescribing competence should require robust GB-based assessment in addition to the Common Registration Assessment. The consultation proposes that all candidates will continue to sit the Common Registration Assessment and that independent prescribing learning-in-practice hours will match those required for existing pharmacist independent prescribing courses^​1​. The final standards should make clear how clinical assessment, diagnostic reasoning, prescribing accountability and referral decisions will be assessed in the GB clinical context before prescribing status is awarded.

The regulator should not treat a shorter route as justified merely because it is faster, cheaper or more flexible. The appropriate test is whether the GPhC can demonstrate that the revised route provides a consistent, evidence-based and publicly defensible pathway to the same register and the same prescribing responsibilities. That requires more than learning outcomes and provider discretion. It requires published evidence of upstream equivalence, national safeguards and transparent accountability.